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DEK is a biochemically distinct protein that is generally found in the nucleus, where it is vital to global
heterochromatin integrity. However, DEK is also secreted by cells (eg, macrophages) and influences other
adjacent cells (eg, acts as a chemoattractant for certain mature blood cells). We hypothesized that DEK may
modulate functions of hematopoietic stem (HSCs) and progenitor (HPCs) cells. C57Bl/6 mice were used to
demonstrate that absolute numbers and cycling status of HPCs (colony forming unit-granulocyte macrophage
[CFU-GM], burst forming unit-erythroid [BFU-E], and colony forming unit-granulocyte erythroid macrophage
megakaryocyte [CFU-GEMM]) in bone marrow (BM) and spleen were significantly enhanced in DEK -/- as
compared with wild-type (WT) control mice. Moreover, purified recombinant DEK protein inhibited colony
formation in vitro by CFU-GM, BFU-E, and CFU-GEMM from WT BM cells and human cord blood (CB) cells in
a dose-dependent fashion, demonstrating that DEK plays a negative role in HPC proliferation in vitro and
in vivo. Suppression was direct acting as determined by inhibition of proliferation of single isolated CD34 + CB
cells in vitro. In contrast, DEK -/ - BM cells significantly demonstrated reduced long term competitive and
secondary mouse repopulating HSC capacity compared with WT BM cells, demonstrating that DEK positively
regulates engrafting capability of self-renewing HSCs. This demonstrates that DEK has potent effects on HSCs,
HPCs, and hematopoiesis, information of biological and potential clinical interest.
Introduction
Hematopoiesis is regulated by cell-cell and cytokine-cell interactions on hematopoietic stem (HSCs) and
progenitor (HPCs) cells [1]. Extracellular and intracellular
players involved in this regulation continue to be identified,
and understanding these factors is crucial to modulating
hematopoiesis for clinical benefit.
In our continuing efforts to elucidate players involved in
regulation of HSC and HPC growth [1], we focused on DEK,
an abundant and unusual protein found in multicellular
organisms [2]. DEK has 2 DNA binding modules and has
some affinity for specific DNA sequences, but primarily
recognizes and binds to superhelical and cruciform DNA
and induces positive supercoiling. DEK manifests multiple
cellular activities that include transcriptional repression and
activation, mRNA processing, and chromatin architectural
functions [2]. We recently demonstrated that DEK modulates
global heterochromatin integrity in vivo [3]. Interestingly,
DEK, an autoantigen in juvenile idiopathic arthritis ( JIA), can
leave the cell and act as a chemoattractant for CD8 +T cells
and natural killer cells [4]. Its secretion from macrophages is
modulated by casein kinase 2 and interleukin (IL)-8, while
being inhibited by dexamethasone and cyclosporine A [5].
Further, DEK is present in synovial fluid and in immune
complexes of patients with JIA, and the chemotactic activity
of DEK suggest that DEK may contribute to joint inflam-
mation [4]. DEK autoantigenicity is augmented by acetyla-
tion. DEK is an oncogene that is overexpressed in multiple
different malignancies [6,7], and is involved in melanoma
proliferation and chemoresistence [6,7], promotion of epi-
thelial transformation in vitro and in vivo [8], and in the
pathogenesis of breast cancer [9].
Being intrigued that a nuclear protein was able to be se-
creted by hematopoietic cells, and act on other hematopoietic
cells, we hypothesized that DEK might play a role in HSC/
HPC function and hematopoiesis. Towards this possibility,
we utilized recombinant (r) DEK protein, and DEK -/ -
mice, to demonstrate that DEK is a positive regulator of long-
term repopulating HSC proliferation and engraftment, and a
negative regulator of HPC proliferation.
Materials and Methods
Recombinant human His-DEK
Recombinant human His-DEK (rhu DEK) was purified
from insect cells essentially as described [10].
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Three days postinfection with a high-titer virus stock,
HighFive cells were harvested and washed 3 times with
phosphate-buffered saline prior to lysis with 2mL of lysis
buffer per 175-cm2 flask (100mM Tris-Cl (pH 7.5), 150mM
NaCl, 5mMKCl, 0.5mMMgCl2, 1%NP-40, 5mM imidazole).
The lysate was further treated with 1.3M NaCl for 20min at
room temperature, cleared (100,000 g, 10min), and diluted
with lysis buffer to a final concentration of 700mM NaCl.
After incubation for 1 h at 4C with Ni-nitrilotriacetic acid-
agarose (Qiagen), the beads were washed 3 times with 10
volumes of buffer 1 [50mM Tris-Cl (pH 7.5), 150mM NaCl,
50mM imidazole], 3 timeswith 10 volumes of buffer 2 [50mM
Tris-Cl (pH 7.5), 300mM NaCl, and 50mM imidazole], and
again with 10 volumes of buffer 1. Elution was performed
with 50mM Tris-Cl (pH 7.5)-150mM NaCl-500mM imidaz-
ole. Aliquots of recombinant protein were stored at - 80C.
DEK - / - mice
These mice (C57BI/6/129/SVEV) were obtained from Dr.
Gerard Grosveld, St Jude Children’s Hospital, Memphis, TN
[8], and were generated at the University of Michigan to a
C57Bl/6 background by back-breeding the -/ - mice with
WT C57BI/6 mice for 9 generations. Mice were housed in
specific pathogen-free conditions at the Animal Maintenance
Facility of the University of Michigan Medical Center and
used at Indiana University for experiments at 10–13 weeks of
age. The University of Michigan and Indiana University
Committees on Use and Care of Animals reviewed and
approved the animal protocols.
HPC assay
C57Bl/6 mouse bone marrow (BM) and spleen cells were
plated respectively at 5· 104 and 5· 105 cells/mL in 1%
methylcellulose culture medium in the presence of hemin
0.1mM, 30% fetal bovine serum (FBS; Hyclone), and the
following growth factors, unless otherwise noted: [1U/mL
rhu erythropoietin (EPO; Amgen), 50 ng/mL recombinant
murine (rmu) stem cell factor (SCF; R&D Systems), and 5%
vol/vol pokeweed mitogen mouse spleen cell conditioned
medium (PWMSCM)] [11]. Colonies were scored after 7 days
incubation at 5% C02 and lowered (5%) 02 in a humidified
chamber and granulocyte macrophage (CFU-GM), erythroid
(BFU-E), and multipotent (CFU-GEMM) progenitors distin-
guished. When other growth factor combinations were used
for stimulation of CFU-GM-derived colonies, no hemin was
added.Human cord blood (CB) cells were separated into a low
density fraction, and plated at 5· 104 cells/mL in 1% meth-
ylcellulose culture media with 30% FBS, and various rhu
cytokines (EPO, 1U/mL; IL-3, 10 ng/mL; granulocyte mac-
rophage-colony stimulating factor (GM-CSF), 10 ng/mL; SCF,
50ng/mL) as noted. rmu and rhu GM-CSF, rmu macrophage
(M)-CSF, rmu, and rhu IL-3 and rmu and rhu SCF were
from R&D Systems [11]. Before sorting, the CD34+population
of hu CB was enriched via MACS (Miltenyi Biotec). After en-
richment via MACS, cells were stained with FITC-conjugated
anti-CD34 antibodies (Miltenyi Biotec) until sorted by FAC-
SAria (BD Biosciences Immunocytometry Systems). Single
CD34+ cells were directly sorted into 1 well of a 96-well mi-
crotiter plate containing 100mL methylcellulose (1%) culture
medium, containing Iscove’s modified Dulbecco’s medium
(IMDM), 30% FBS, SCF, IL-3, GM-CSF, and EPO [12].
HSC engrafting studies
All mice used were on a C57Bl/6 strain background. BM
cells from DEK -/ - or wild type (WT) control mice
(CD45.2 + ) served as donor cells and were used at a 1:1
(2.5 · 105 to 2.5 · 105) ratio with BoyJ congenic (CD45.1)
competitor cells; they were intravenously transplanted to-
gether into primary F1 (dual CD45.1/CD45.2) mice that were
given a lethal dose (950 cGy) of gamma irradiation [13]. For
secondary transplants BM cells from primary mice engrafted
for 6 months were transplanted at 5 · 105 cells into secondary
lethally irradiated F1 mice in a noncompetitive transplant
assay [13]. Results are given as percent CD45.2 + donor cell
chimerism in the peripheral blood or BM at the times noted.
FIG. 1. Hematopoietic progenitor cell numbers and cycling
characteristics (% in S-Phase of the cell cycle) in bone marrow
(femur) and spleens of DEK -/ - and WT control mice.
Results (mean– 1 SEM) are based on 6 individually assessed
mice per group for each progenitor cell population in a total
of 2 separate experiments. P values compare DEK -/ - with
WT mice. WT, wild type; SEM, standard error of the mean;
CFU-GM, colony forming unit-granulocyte macrophage;
BFU-E, burst forming unit-erythroid; CFU-GEMM, colony
forming unit-granulocyte erythroid macrophage mega-
karocyte.
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Statistical analysis
In vitro and in vivo differences between WT and DEK
-/- mice were assessed by double-tailed student’s t-test. Sig-
nificance for single cell assays was determined by Fischer’s exact
test. P values of at least P<0.05 were considered significant.
Results and Discussion
HPC proliferation in DEK - / - mice
To determine whether DEK had an effect on steady state
hematopoiesis, BM and spleen cells from DEK -/ - mice
were compared with that of WT control mice for absolute
numbers and cycling status of CFU-GM, BFU-E, and CFU-
GEMM. Although there were no differences in BM (Fig. 1a)
or spleen (Fig. 1b) nucleated cellularity between DEK -/ -
and WT mice, the absolute numbers of CFU-GM, BFU-E, and
CFU-GEMM per femur (Fig. 1c) and per spleen (Fig. 1d)
were increased in DEK -/ - mice with significant increases
in BM CFU-GM and CFU-GEMM, and in splenic CFU-GM
and BFU-E. Increases in DEK -/ - progenitors in BM and
spleen were consistent with significantly increased percent-
ages of CFU-GM, BFU-E, and CFU-GEMM in S-Phase of the
cell cycle in DEK -/ - BM (Fig. 1e) and spleen (Fig. 1f ).
FIG. 2. Influence of rhuDEK
on colony formation CFU-GM
(a), BFU-E (b), and CFU-
GEMM (c) in 5· 104 unsepa-
rated WT control mouse bone
marrow cells per milliliter.
Results (mean– 1 SEM) shown
are 1 of 3 reproducible exper-
iments. P values are compared
with control values without
added DEK. Rhu, recombi-
nant human.
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Increased numbers and cycling of HPCs in DEK -/ - BM
and spleen suggest that DEK acts as a negative regulator of
HPC proliferation in vivo.
Influence of rhu DEK on colony formation
in vitro by HPCs
To assess this negative role for DEK further, rhu DEK was
tested for effects on HPC proliferation using unseparated
mouse BM (Fig. 2) and low density hu CB (Fig. 3) cells. DEK,
dose-dependently suppressed colony formation by mouse
BM CFU-GM stimulated by either IL-3 or GM-CSF, each
alone; it did not influence colony formation stimulated by M-
CSF alone (Fig. 2a). However, it dose-dependently inhibited
CFU-GM colony formation by either IL-3, GM-CSF, or M-
CSF when these cytokines were combined with the potent
co-stimulating cytokine SCF. In fact, inhibition by DEK was
greater on CFU-GM stimulated by the combination of IL-3,
GM-CSF, or M-CSF, each in the presence of SCF, compared
with CFU-GM stimulated by IL-3, GM-CSF, or M-CSF each
alone in terms of percent inhibition, and the amount of DEK
required to inhibit colony formation. Although the lowest
amount of DEK that could inhibit colony formation of
CFU-GM stimulated by IL-3 or GM-CSF alone was 10 nM,
concentrations as low as 1 nM DEK could inhibit colony
formation stimulated by IL-3 plus SCF, or GM-CSF plus SCF.
Although DEK did not inhibit colony formation of CFU-GM
stimulated by M-CSF at up to 100 nM, it was active at con-
centrations as low as 10 nM in suppressing M-CSF plus SCF
stimulated colony formation. DEK at concentrations of 10 nM
also inhibited colony formation by BFU-E (Fig. 2b) and by
CFU-GEMM (Fig. 2c) each stimulated by a combination of
growth factors (EPO, PWMSCM, and SCF). It is known that
HPCs stimulated by a single CSF (eg, IL-3, GM-CSF, or M-
CSF) represent a more mature subset of HPCs than those
stimulated by a combination of cytokines (such as a CSF plus
SCF) [1], suggesting that immature subsets of HPCs are more
sensitive in vitro to the suppressive effects of DEK than are
the more mature HPCs.
Similar results were noted for HPCs present in hu CB (Fig.
3). DEK was an inhibitor of CFU-GM (Fig. 3a) and this in-
hibition was greater and apparent at lower concentrations of
DEK when colonies formed from CFU-GM were stimulated
by combinations of cytokines, compared with those stimu-
lated by a single cytokine. Colony formation by BFU-E (Fig.
3b) and CFU-GEMM (Fig. 3c) in hu CB were also suppressed
by DEK.
The activity of DEK in vitro in inhibiting colony formation
by CFU-GM, BFU-E, and CFU-GEMM (Figs. 2 and 3) is
consistent with the increased numbers and cycling of these
progenitors in DEK -/ - compared with WT BM and spleen
(Fig. 1c–f ), confirming the negative regulatory effects of DEK
on proliferation of HPCs. Since the HPCs in Figs. 2 and 3
were present in a relatively unseparated population of
FIG. 3. Influence of rhu DEK on colony formation by CFU-GM (a), BFU-E (b), and CFU-GEMM (c) per milliliter in low
density human cord blood. Results (mean – 1 SEM) shown are 1 of 2 reproducible experiments. P values are compared with
control values without added DEK.
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mouse BM and low density cord blood cells, the suppressive
effects of DEK on colony formation could have been due to
direct effects on the HPCs, or indirectly mediated by effects
on accessory cells. To determine if the DEK effects were di-
rectly or indirectly manifesting on the HPCs, DEK was as-
sessed for effects on single isolated CD34 + cord blood cells
[10], each in a single well stimulated by EPO, GM-CSF, IL-3,
and SCF. As seen in Fig. 4, DEK significantly decreased the
number of wells containing a CFU-GM-, BFU-E-, or CFU-
GEM- colony. The BFU-E effects were borderline significant,
but scoring the numbers of wells with either a BFU-E- or CFU-
GEMM-colony together resulted in inhibition that attained a
P value of P< 0.0013. This demonstrates that DEK directly
initiates its suppressive effect onHPC. This however, does not
rule out the possibility that DEK may also act on other, pos-
sibly accessory, cells to influence HPC proliferation.
Engrafting capability of DEK - /- mouse BM cells
The competitive repopulating assay in vivo allows as-
sessment of the short- and longer-term repopulating HSC,
and transplantation of BM cells from primary to secondary
lethally-irradiated recipients in a noncompetitive assay de-
scribes the longer-term repopulating HSC [1,14], and can
offer information on the self-renewal capacity of this popu-
lation of HSCs. As shown in Fig. 5a, although there was no
difference in the HSC repopulating capacity of DEK -/ -
and WT shorter-term repopulating cells (months 1 and 2 for
blood chimerism), there was a significant decrease in DEK
-/ - compared with WT BM cell repopulation at month 4 in
the blood, and month 6 in the BM. This decreased re-
population of DEK -/ - compared with WT HSC was even
more apparent in secondary mouse recipients (Fig. 5b) sug-
gesting that DEK played a positive role in engraftment of
longer-term repopulating HSCs, and perhaps in the self-
renewal capacity of mouse BM HSCs. Exactly how DEK acts
to influence long term repopulating self-renewing HSCs re-
mains to be determined. The effects may be direct acting on
the HSCs, or indirectly mediated by accessory cells in the
mouse.
The studies shown in Figs. 1–5 demonstrate a here-to-fore
unknown role for DEK in the regulation of HPCs, HSCs, and
hematopoiesis. DEK could have separate effects on HPC and
HSC, as suggested by the direct acting effects of DEK on
single HPC. Alternatively, DEK may alone or in addition
allow HSC to favor a self-renewal, versus a differentiation
pathway to HPC. Exactly how DEK mediates this regulation
FIG. 4. Influence of rhu DEK directly on hematopoietic
progenitor cells. DEK was assessed on colony formation by
single isolated CD34 + human cord blood cells each in a
single well. Results (mean – 1 standard deviation) of each
experimental point are based on analysis of 288 wells.
FIG. 5. Primary and sec-
ondary engrafting capability
of DEK -/- and WT control
donor hematopoietic stem
cells. Experiments were de-
signed as noted in the Mate-
rials and Methods section.
Results are given as donor cell
(CD45.2+ ) chimerism in blood
and bone marrow of lethally-
irradiated (F1; dual CD45.2+/
CD45.1+ ) recipients. Primary
engraftment was with com-
petitor cells (BoyJ; CD45.1+ );
secondary transplants did not
use additional competitor
cells. Results are expressed as
mean– 1 SEM. For primary
transplants, bone marrow
cells from 2 WT and 2 DEK
-/- mice were used. Cells
from each mouse were com-
bined with competitor cells
and intravenously infused into 5 lethally irradiated recipients each for WT cells, and into 4 and 5 recipients each for DEK -/-
cells cells, for a total of 10 primary recipients for WT and 9 primary recipients for DEK -/- . Bone marrow from each group of
primary mice, 6 months after transplant were separately pooled (10 for WT; 9 for DEK -/- ) and these pools injected without
additional competitor cells into 10 (WT) and 9 (DEK -/- ) recipients.
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in the cell is not yet known. This may entail transcriptional
effects. DEK is heavily posttranslationally modified, and is
acetylated in vivo at lysine residues in the first 70 N-terminal
amino acids [15]. Both acelylation and phosphorylation of
DEK decrease its affinity for DNA elements in transcriptional
promoter regions, consistent with its involvement in tran-
scriptional modulation [3,6,10]. Our recent observation that
DEK is vital to global heterochromatin integrity in vivo
suggests that this activity may also play a role in the way
DEK affects hematopoiesis [3].
It is possible that DEK may be of potential clinical value
for enhancing HSC activity/proliferation in vivo, or in an ex-
vivo situation. Either of these possibilities would have clin-
ical applicability and relevance, and further assessment of
these activities are warranted.
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